Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High Risk Pancreatic Neuroendocrine Tumors
For more information about the trial above please contact the study team:
Principal Investigator, William Lancaster, at firstname.lastname@example.org.
Study Coordinator, Carly Fecio, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina